PDX Pharmaceuticals

PDX Pharmaceuticals started in 2010 as a spinoff from the Biomedical Engineering Department at OHSU. The company has developed novel cancer therapeutics by combining nanotechnology and cancer systems biology in collaboration with the Knight Cancer Institute (KCI) of OHSU. PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE™) and is raising $15M to initiate the clinical trial of AIRISE™ in 2022 and advance ARAC™ to clinics by 2023.

Rezolute, Inc.

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.


Senju Pharmaceutical develops health care products for the ears, eyes, nose, skin and throat. For nearly three decades, Senju has developed ophthalmological products, recently diversifying into other areas that ensure the healthy functioning of our senses. Senju collaborates with international research initiatives, academic institutions and researchers, and industry specialists to unlock medical secrets that lead to pharmaceutical breakthroughs.

Core Member: Sparrow Pharmaceuticals

Nearly 2 million Americans are on long-term corticosteroid therapy to treat diseases such as rheumatoid arthritis, asthma, vasculitis, and blood cancers. To control their disease those patients face the high adverse effects risk of corticosteroids. Drug adverse effects, of which corticosteroids are responsible for 10%, cost up to $30B per year in the US.

Sparrow Pharmaceuticals is developing safer corticosteroids. Those will provide patients a new standard of care that is effective, safe, cost-effective, and convenient. A tablet form will start […]


UbiVac is a company that offers a pipeline of groundbreaking immunotherapies in preclinical and clinical stage trials. Since 2005 the company has been engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.

UbiVac’s lead product, DPV-001 (DRibble) is a first in class DC-targeted complex vaccine/combination immunotherapy that is now in Phase II clinical trials for lung cancer. A pilot study of the vaccine is open for patients with prostate cancer, and a Phase […]

Veana Therapeutics

VEANA THERAPEUTICS, INC is a privately held Oregon-based biotechnology company whose business strategy is to identify Alpha-TEA (vitamin E analog) cancer immunotherapy technologies.  Established in 2012, it is based on the work of its founder, Dr. Emmanuel Akporiaye.

Alpha-TEA immunotherapy technologies are based on orally bioavailable anti-cancer agents that simultaneously kill tumor cells and stimulate the immune system.  Alpha TEA’s can be combined with other forms of immunotherapy to further improve their anti-tumor activity.


Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Lead investors include ARCH Venture Partners and the Bill & Melinda Gates Foundation, and will […]